Related Experiment Video
Updated: Apr 24, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer
Sweta Mishra, Chun-Lin Lin, Tim H-M Huang
1Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7762, San Antonio, TX 78229-3900, USA. sunl@uthscsa.edu.
Background:
p57(Kip2), a cyclin-dependent kinase inhibitor, is considered to be a candidate tumor suppressor gene that has been implicated in Beckwith-Wiedemann syndrome and sporadic cancers. In addition, decreased expression of p57(Kip2) protein has been frequently observed in pancreatic, lung, breast, bladder, gastrointestinal tract and prostate cancers. However, p57(Kip2) gene mutations are rare in these cancers suggesting that other unknown mechanisms might be at play in reducing its expression. The aim of this study was to investigate the molecular mechanism of down-regulation of p57(Kip2) in prostate cancer.
Findings:
We observed a significant negative correlation between the expression of p57(Kip2) and microRNA-21 (miR-21) in prostate cancer samples and after androgen deprivation with castration in the CWR22 human prostate cancer xenograft model. We report that miR-21 targeted the coding region and decreased p57(Kip2) mRNA and protein levels in prostate cancer cells. Conversely, inhibition of endogenous miR-21 by an anti-miR-21 inhibitor strongly induced p57(Kip2) expression. Furthermore, we found that knockdown of p57(Kip2) reversed the effects of the anti-miR-21 inhibitor on cell migration and anchorage-independent cell growth.
Conclusions:
Our results indicate that miR-21 is able to downregulate p57(Kip2) expression by targeting the coding region of the gene and is also able to attenuate p57(Kip2) mediated functional responses. This is the first report demonstrating that p57(Kip2) is a novel target of miR-21 in prostate cancer and revealing a novel oncogenic function of this microRNA.
Insights
MicroRNA-21 (miR-21) downregulates the tumor suppressor p57(Kip2) in prostate cancer by targeting its coding region. This interaction reveals a new mechanism for cancer development and a novel oncogenic role for miR-21.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- p57(Kip2) is a cyclin-dependent kinase inhibitor and a potential tumor suppressor.
- Decreased p57(Kip2) expression is common in various cancers, including prostate cancer.
- Mutations in p57(Kip2) are rare, suggesting other regulatory mechanisms are involved.
Purpose of the Study:
- To investigate the molecular mechanisms behind p57(Kip2) downregulation in prostate cancer.
- To determine the role of microRNA-21 (miR-21) in regulating p57(Kip2) expression.
Main Methods:
- Correlation analysis between p57(Kip2) and miR-21 expression in prostate cancer samples.
- In vitro studies using prostate cancer cells to assess miR-21 targeting of p57(Kip2).
- Experiments involving anti-miR-21 inhibitors and p57(Kip2) knockdown.
Main Results:
- A significant negative correlation was observed between p57(Kip2) and miR-21 expression.
- miR-21 directly targets the coding region of p57(Kip2), reducing its mRNA and protein levels.
- Inhibition of miR-21 increased p57(Kip2) expression and reversed effects on cell migration and growth.
Conclusions:
- miR-21 downregulates p57(Kip2) expression and its functional responses in prostate cancer.
- p57(Kip2) is identified as a novel target of miR-21 in prostate cancer.
- This study reveals a new oncogenic function for miR-21 in prostate cancer development.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Abnormal Proliferation
Negative Regulator Molecules
Experimental RNAi

